Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Biotechnology


  • Biotechs rally back Monday, 24 Aug 2015 | 2:25 PM ET
    Biotechs rally back

    Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.

  • Aug 21- The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug. The study, among patients with newly diagnosed brain cancer, is being conducted in Germany, the United Kingdom, the United States...

  • Time for biotech to bounce back? Monday, 17 Aug 2015 | 2:35 PM ET
    Time for biotech to bounce back?

    David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.

  • Bass's biotech beef Wednesday, 12 Aug 2015 | 5:15 PM ET
    Bass's biotech beef

    One biotech stock could see massive moves later this month, thanks to the meddling of hedge fund heavy hitter, Kyle Bass. CNBC's Meg Tirrell reports the latest.

  • Has biotech peaked? Wednesday, 12 Aug 2015 | 2:43 PM ET
    Has biotech peaked?

    The ETF that tracks biotechs, BBH, is up nearly 16 percent to date. Dominic Chu looks at whether there's still more room to run.

  • Australia’s CSL warns of biotech bubble Monday, 10 Aug 2015 | 7:26 PM ET
    CSL employees.

    CSL has warned of a "biotech bubble" amid a frenzy of mergers and acquisition activity across the healthcare sector, the Financial Times reports.

  • IBB claws its way back Monday, 10 Aug 2015 | 2:08 PM ET
    IBB claws its way back

    The Nasdaq biotech ETF IBB is coming back after tumbling more than 4 percent toward the end of last week. Is now the time to buy, with Eric Schmidt, Cowen & Co., and John Sonnier, with William Blair & Co.

  • Teva to acquire Allergan for $40B Monday, 27 Jul 2015 | 11:11 AM ET
    Teva to acquire Allergan for $40B

    A major deal in the pharma space, Teva says it will buy Allergan's generics business in a deal worth a little over 40 billion dollars. CNBC's Meg Tirrell reports the details.

  • First Malaria vaccine Friday, 24 Jul 2015 | 4:24 PM ET
    First Malaria vaccine

    Insight on malaria prevention, with Monceff Slaoui, GlaxoSmithKline, who is committed to the social responsibility of saving lives.

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • This will change the face of human health: Pro Friday, 19 Jun 2015 | 1:36 PM ET
    This will change the face of human health: Pro

    CNBC's Meg Tirrell dives into how J&J plans to tackle autoimmune disease and why health care professionals say the microbiome "is going to change the face of human health."

  • Healthcare takeover targets Friday, 19 Jun 2015 | 1:17 PM ET
    Healthcare takeover targets

    In terms of deal value, healthcare has logged the most M&A activity this year, according to Dealogic, after taking the top spot in both 2014 and 2013. CNBC's Morgan Brennan reports.

  • Suberbug-fighting startup Friday, 19 Jun 2015 | 11:47 AM ET
    Suberbug-fighting startup

    Seres Therapeutics has filed to go public, ticker MCRB (for microbiome). CNBC's Meg Tirrell explains why it has breakthrough therapy designation from the FDA.

  • Avalanche CEO: Disappointed in market's reaction of study

    Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.

  • The pharma sector is exciting, says Wells Fargo Wednesday, 10 Jun 2015 | 7:24 PM ET
    The pharma sector is exciting, says Wells Fargo

    Margaret Patel, senior portfolio manager & managing director at Wells Fargo Advantage Funds, explains why she likes U.S. pharmaceutical stocks.

  • Contrarian biotech play Tuesday, 26 May 2015 | 5:28 PM ET
    Contrarian biotech play

    David Seaburg of Cowen has a way to trade pharma stocks into the ASCO meeting. He breaks it down, with Stacey Gilbert of Susquehanna and Brian Sullivan.

  • Moderna Therapeutics No. 1 on Disruptor 50: Here's why Tuesday, 12 May 2015 | 11:43 AM ET
    Moderna Therapeutics No. 1 on Disruptor 50: Here's why

    Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.

  • Is the market leadership changing? Thursday, 30 Apr 2015 | 5:00 PM ET
    Is the market leadership changing?

    Are transport stocks and biotechs giving up their market leadership? Andrew Burkly of Oppenheimer and Rich Ross of Evercore ISI discuss with Brian Sullivan.

  • Promising cancer drugs Friday, 17 Apr 2015 | 4:42 PM ET
    Promising cancer drugs

    The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.

  • This is what's driving biotech Wednesday, 8 Apr 2015 | 5:30 AM ET
    This is what's driving biotech

    Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.